Navigation Links
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
Date:9/13/2011

EXTON, Pa., Sept. 13, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today  that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 esterase inhibitor [human)] in combination with Halozyme's Enhanze™ technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20), in subjects with hereditary angioedema (HAE).  Initiation of the clinical trial has triggered a milestone payment of $3 million to Halozyme.

"Routine prophylaxis with intravenous Cinryze has transformed the management of HAE for many patients who also have the option for self administration. The initiation of this first phase 2 study with a novel, subcutaneous combination product represents an exciting new development for patients and their physicians and is an important milestone for ViroPharma," commented Jennifer Schranz, MD, ViroPharma's vice president, clinical research. "Our goal is to optimize the overall convenience of self-administration therapy with a single subcutaneous injection. This is an important part of our efforts to continually enhance the Cinryze experience for both existing and future patients by providing them an alternative administration option."

"The start of this Phase 2 subcutaneous trial in patients with HAE marks a great achievement for our partnership with ViroPharma, and I congratulate the team on this important accomplishment," said Gregory Frost, Ph.D., Halozyme's president and CEO. "Cinryze is the only HAE therapy approved for both routine prophylaxis against attacks along with self administration, and we expect this subcutaneous alterna
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
2. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
3. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
4. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
5. ViroPharma to Participate in the Jefferies 2011 Global Healthcare Conference
6. ViroPharma Launches Swell, an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
7. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
8. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
9. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
10. ViroPharma to Participate In Three May Healthcare Investor Conferences
11. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 InfinityQS ... and Manufacturing Intelligence , today announces Infusion ... The event will be held Oct. 9-10, 2014, ... is designed to showcase the necessity for implementing ... metrics and Manufacturing Intelligence to gain insight into ...
(Date:8/21/2014)... -- Professional Compounding Centers of America (PCCA) will ... three best scientific presentations at the sixth ... Formulating Better Medicines for Children  conference, held ... Greece , includes dozens of poster-style scientific ... three winners will be selected by a panel ...
(Date:8/21/2014)... MENLO PARK, Calif. , Aug. 21, 2014 /PRNewswire/ ... company in the emerging field of regenerative medicine, announced ... ("Nat") Ricciardi to the Company,s newly expanded Board of ... now comprises eight directors, three of whom are independent. ... years of experience working with emerging growth companies. He ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4
(Date:8/21/2014)... The International and American Associations for Dental Research (IADR/AADR) ... Prevalence Following Five Decades of Decline." This study, by ... Chapel Hill, USA, follows edentulism (tooth loss) over the ... losing teeth and requiring dentures. It is published in ... Dental Research ( JDR ). , The ...
(Date:8/21/2014)... United Benefit Advisors (UBA), the ... pleased to announce Trinity Benefit Advisors as its ... Trinity Benefit Advisors is a full service firm ... clients. Their consultative approach is comprised of four ... and monitoring. Their dedication to effective results and ...
(Date:8/21/2014)... York (PRWEB) August 21, 2014 According ... Research "Enteral Feeding Devices Market (Enteral Feeding Tubes, Enteral ... - Global Industry Analysis, Size, Share, Growth, Trends and ... was valued at USD 2.0 billion in 2012 and ... 3.1 billion in 2019growing at a CAGR of 6.2% ...
(Date:8/21/2014)... authorities need to ensure that experimental drugs to treat ... randomized controlled trials, according to a new Viewpoint, published ... 2014]. , Leading bioethicists Professor Ezekiel Emanuel, ... Annette Rid, of King,s College London, UK, outline critical ... experimental drugs are to be deployed in the Ebola ...
(Date:8/21/2014)... Albany, NY (PRWEB) August 21, 2014 ... 2020 - Novel Therapeutic Approaches Target High Unmet ... provides in-depth analysis of the Glioblastoma Multiforme (GBM) ... Australia, China, India and Japan. The report provides ... market forecasts until 2020. It also covers disease ...
Breaking Medicine News(10 mins):Health News:Study shows steep decline in tooth loss, increase in socioeconomic disparities 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 2Health News:Trinity Benefit Advisors is the Latest Firm to Join United Benefit Advisors 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Enteral Feeding Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:The Lancet: Experimental Ebola drugs must be fairly distributed and tested ethically in clinical trials 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 3Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 4Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 5Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 6Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 7
... window of vulnerability for developing binge eating disorder, especially ... study from the University of North Carolina at Chapel ... long-term study of 100,000 pregnant Norwegian women, the researchers ... eating disorder that began during pregnancy. The research is ...
... By furthering scientists understanding of the molecular mechanisms that ... majority of ineffective antibodies, the work may have implications ... The study was published on September 6, 2007, in ... of the effort to understand how protection against HIV ...
... to Peter B. Ajluni, D.O., American Osteopathic,Association (AOA) President, ... of,Americans without health insurance to 47 million --- as ... --- is a disturbing trend signaling,more must be done ... As lawmakers return this week from the summer recess, ...
... Sept. 6 H.E.A.R.T 911 is a,non-profit, non-sectarian ... fighters and construction trade union workers, all of,whom ... 11th attacks and,surviving family members of those who ... nation-wide to situations that arise during,natural or man-made ...
... promotes free quit-smoking services from ClearWay ... ... a,dramatic new billboard will catch the eye of motorists on Interstate ... a,giant ashtray, the billboard will call attention to QUITPLAN(R) Services,Clearway Minnesota,s ...
... Interactive Workshop Features CML Expert, Jorge Cortes, M.D., ... an,expert on leukemia, will discuss novel treatment approaches for ... CML: A,Model in Cancer Therapy. The program is scheduled ... ET. The program is being offered by The ...
Cached Medicine News:Health News:Pregnancy may increase the risk of developing binge eating disorder 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 2Health News:Scripps Research scientists shed new light on how antibodies fight HIV 3Health News:Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911. 2Health News:Award-winning QUITPLAN(R) Services Billboard Debuts in Rogers 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 2Health News:The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: